Loading
A phase 2 trial of IN10018, Pegylated liposomal doxorubicin in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06014528 by InxMed (Shanghai) Co., Ltd., with 168 participants planned, started 2022-09-06 and due to reach its primary completion in 2026-12-24. Interventions recorded: IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Shares InxMed, IN10018, Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/